Core Viewpoint - The company, 石四药集团 (Sihuan Pharmaceutical Holdings Group Ltd), is expected to have a positive impact on its business due to the anticipated successful bids for 45 product varieties in the upcoming national centralized procurement in China scheduled for February 10, 2026 [1] Group 1: Product Categories - The 45 product varieties cover multiple therapeutic areas including anti-infection, cardiovascular system, respiratory system, digestive system, and nervous system [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, announced that it is expected to win bids for 45 products in the upcoming national centralized procurement in China, which is anticipated to positively impact its business [1] Group 1: Product Categories - The 45 products cover various therapeutic areas including anti-infection, cardiovascular system, respiratory system, digestive system, and nervous system [1]

石四药集团(02005)发布公告，于2026年2月10日的中国第一至八批全国药品集中采购(国家集采)的接续 采购中，集团共45个品种的产品拟中标，涵盖抗感染、心血管系统、唿吸系统、消化系统、神经系统等 治疗领域，预期对集团的业务带来正面影响。 ...

智通财经APP讯，石四药集团(02005)发布公告，于2026年2月10日的中国第一至八批全国药品集中采购 (国家集采) 的接续采购中，集团共45个品种的产品拟中标，涵盖抗感染、心血管系统、唿吸系统、消化 系统、神经系统等治疗领域，预期对集团的业务带来正面影响。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 於二零二六年二月十日的中國第一至八批全國藥品集中採購（「國家集採」）的接續採購中，本 集團共45個品種的產品擬中標，涵蓋抗感染、心血管系統、呼吸系統、消化系統、神經系統等 治療領域，預期對本集團的業務帶來正面影響。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二六年二月十日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 自願公告 國家集採接續採購 擬中選結果 ...

Financial Overview - The company reported total revenue of CNY 152,074,731.41 for the first half of 2025, a decrease from CNY 221,933,271.08 in the same period of 2024, representing a decline of approximately 31.4% [4][5] - Total operating costs for the first half of 2025 were CNY 197,899,171.63, down from CNY 228,077,115.52 in the previous year, indicating a decrease of about 13.3% [4][5] - The net profit for the first half of 2025 was CNY 105,176,469.82, compared to a net profit of CNY 5,475,173.86 in the first half of 2024, showing a significant increase [5][6] Assets and Liabilities - Total assets at the end of the first half of 2025 amounted to CNY 1,504,030,958.30, down from CNY 1,757,857,969.48 at the beginning of the period, reflecting a decrease of approximately 14.4% [3][4] - Total liabilities decreased to CNY 318,614,658.60 from CNY 647,661,753.51, a reduction of about 50.8% [3][4] - The total equity attributable to shareholders increased to CNY 1,185,416,299.70 from CNY 1,110,196,215.97, marking an increase of approximately 6.7% [4][5] Cash Flow - The net cash flow from operating activities for the first half of 2025 was CNY 27,896,651.19, compared to CNY 32,398,357.90 in the same period of 2024, indicating a decrease [6][7] - Cash flow from investing activities showed a net inflow of CNY 175,946,706.63, a significant improvement from a net outflow of CNY 4,386,493.11 in the previous year [6][7] - Cash flow from financing activities resulted in a net outflow of CNY 314,596,678.34, compared to a net outflow of CNY 61,901,761.80 in the same period of 2024 [6][7] Earnings Per Share - Basic and diluted earnings per share for the first half of 2025 were both CNY 0.14, compared to CNY 0.01 in the same period of 2024, indicating a substantial increase in profitability per share [5][6]

Core Viewpoint - *ST Suwu has shown a significant increase in stock price and strong financial performance, indicating potential growth in the pharmaceutical and medical beauty sectors [1][2]. Group 1: Company Overview - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is located at 988 Dongfang Avenue, Wuzhong District, Suzhou, and operates in the pharmaceutical, medical beauty, and investment industries [1]. - The company's pharmaceutical products cover areas such as antiviral/infection control, immune regulation, anti-tumor, digestive system, and cardiovascular fields [1]. - The medical beauty segment holds exclusive agency rights for Korean medical beauty products in China [1]. - The company aims to develop a health industry cluster with a focus on pharmaceutical health and emerging sectors like medical beauty in its 2020-2024 strategic plan [1]. Group 2: Financial Performance - As of September 30, *ST Suwu had 61,600 shareholders, with an average of 11,500 circulating shares per shareholder [2]. - For the period from January to September 2024, *ST Suwu achieved a revenue of 1.647 billion yuan, representing a year-on-year growth of 9.58% [2]. - The net profit attributable to shareholders for the same period was 45.08 million yuan, showing a substantial year-on-year increase of 311.54% [2].

Group 1 - The stock price of Fuyuan Pharmaceutical closed at 31.67 yuan on August 15, 2025, down 0.66% from the previous trading day [1] - The stock experienced significant volatility, with a high of 32.60 yuan and a low of 30.48 yuan, resulting in an amplitude of 6.65% [1] - The total trading volume for the day was 200,306 hands, with a transaction amount of 628 million yuan [1] Group 2 - Fuyuan Pharmaceutical is primarily engaged in chemical pharmaceuticals and medical devices, covering multiple therapeutic areas including cardiovascular, digestive, and anti-infection [1] - The company is headquartered in Beijing and is one of the stocks included in the Shanghai-Hong Kong Stock Connect [1] - A half-year performance briefing is scheduled for August 22, 2025, where the chairman and general manager will interact with investors online [1] Group 3 - On August 15, 2025, the net outflow of main funds was 36.41 million yuan, accounting for 0.24% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 61.33 million yuan, representing 0.4% of the circulating market value [1]

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Wuzhong*) is facing potential forced delisting due to continuous financial fraud over four years, with the China Securities Regulatory Commission (CSRC) proposing a fine of 10 million yuan and indicating a "zero tolerance" stance towards such violations [1][5]. Group 1: Financial Misconduct - *ST Wuzhong* has been found to have falsified financial reports from 2020 to 2023, inflating revenue by 4.95 billion yuan, 4.69 billion yuan, 4.31 billion yuan, and 3.77 billion yuan, which accounted for 26.46%, 26.39%, 21.26%, and 16.82% of the reported revenue for those years respectively [2]. - The company also inflated total profits by 14.58 million yuan, 20.27 million yuan, 19.92 million yuan, and 21.22 million yuan, representing 2.89%, 51.65%, 26.42%, and 29.81% of the total profits for the respective years [2]. - Additionally, *ST Wuzhong* failed to disclose significant non-operating fund occupation by related parties, with amounts reaching 1.27 billion yuan, 1.39 billion yuan, 1.54 billion yuan, and 1.69 billion yuan from 2020 to 2023, which constituted 6.88%, 74.2%, 84.6%, and 96.09% of the net assets for those years [2]. Group 2: Regulatory Actions - The CSRC plans to impose a total fine of 30.5 million yuan on *ST Wuzhong* and its responsible individuals, with the actual controller, Qian Qunshan, facing a proposed 10-year ban from the securities market due to severe misconduct [3]. - Starting July 14, *ST Wuzhong*'s stock will be subject to delisting risk warnings due to its financial fraud, which has already led to previous warnings and a lack of opinion from the auditing firm on its 2024 financial report [4]. - The company has expressed its intention to cooperate with the CSRC and will exercise its rights to defend against the proposed penalties [4].

Core Viewpoint - *ST Suwu is facing potential delisting due to significant violations, including continuous financial fraud and misleading disclosures, as indicated by the China Securities Regulatory Commission (CSRC) [1][6] Group 1: Violations and Penalties - The company has been found guilty of failing to disclose the actual controller from 2018 to 2023, misrepresenting Qian Qunshan as the actual controller instead of the true controller [2] - *ST Suwu inflated its operating income, operating costs, and profits from 2020 to 2023, with inflated revenues of 495 million, 468 million, 431 million, and 377 million respectively, accounting for 26.46%, 26.39%, 21.26%, and 16.82% of reported revenues [3] - The company failed to disclose significant non-operating fund occupation by related parties, with balances of 127 million, 1.393 billion, 1.543 billion, and 1.693 billion from 2020 to 2023, representing 6.88%, 74.2%, 84.6%, and 96.09% of net assets [4] Group 2: Regulatory Actions - The CSRC plans to impose a fine of 10 million on *ST Suwu and additional fines on key executives, including 15 million on Qian Qunshan, 2 million on Qian Qunying, and 1.5 million on Chen Yi [5] - Qian Qunshan is also facing a 10-year ban from the securities market due to the severity of his actions as the actual controller and chairman [5] - The company acknowledges the potential for mandatory delisting and plans to cooperate with the CSRC while maintaining that its operations are normal as of the announcement date [6]